25,729 articles
Vosilasarm
Vosilasarm (RAD140, testolone, EP0062) is an oral non-steroidal selective androgen receptor modulator in phase 1/2 trials for AR+/ER+/HER2- breast cancer; not FDA approved.
Vosoritide
Vosoritide (Voxzogo, BMN 111) is a 39-amino-acid C-type natriuretic peptide analog by BioMarin that binds NPR-B to counteract FGFR3 signaling, increasing linear growth in children with achondroplasia; approved from 2021 in the EU, US, Japan, and Australia.
Votumumab
Votumumab (HumaSPECT, clone 88BV59) is a human IgG3 monoclonal antibody against cytokeratin tumor-associated antigens, labeled with technetium-99m to image colorectal cancer recurrence; EU-authorized 1998, withdrawn 2003, never marketed.
Vox sanguinis
Vox sanguinis (voice of blood) is the official journal of the International Society of Blood Transfusion, published monthly by Wiley; founded in Amsterdam in 1951, renamed 1953, covering transfusion medicine from donor to recipient.
Voxel-based morphometry
Voxel-based morphometry (VBM) is an MRI neuroimaging method comparing gray matter voxel-wise between groups via normalization, segmentation, smoothing, and statistical parametric mapping; introduced by Ashburner and Friston (2000), distinct from surface-based morphometry.
Voxelotor
Voxelotor (Oxbryta, GBT440) was an oral HbS polymerization inhibitor for sickle cell disease, FDA-accelerated-approved in 2019 and withdrawn worldwide by Pfizer in September 2024 over vaso-occlusive crisis safety signals.
Voxilaprevir
Voxilaprevir (GS-9857) is a Gilead HCV NS3/4A protease inhibitor used only in Vosevi (sofosbuvir/velpatasvir/voxilaprevir), the 12-week salvage regimen for DAA treatment failures, FDA approved 2017.
Voxinkibart (伏欣奇拜单抗) injection
Voxinkibart (伏欣奇拜单抗), also known as firsekibart or Genakumab, is a monoclonal antibody drug for acute gouty arthritis developed by GenSci and approved in China in 2025.
VOYAGER PAD trial
VOYAGER PAD (NCT02504216) was a phase 3 trial of rivaroxaban 2.5 mg twice daily plus aspirin versus aspirin alone after lower-extremity revascularization in 6,564 PAD patients, reducing the composite limb and cardiovascular endpoint (HR 0.85) without significant TIMI major bleeding excess.
Voyeuristic disorder
Voyeuristic disorder (ICD-11 6D31; DSM-5-TR 302.82/F65.3 lineage) is a paraphilic disorder: recurrent intense arousal from observing unsuspecting people naked, disrobing, or having sex, acted on or causing distress, diagnosed only in adults after 6 months.
VRandMRI study
VRandMRI (NCT05098587) is a completed observational pilot study by Swiss Paraplegic Research, Nottwil, testing whether Virtual Walk therapy changes pain perception, BOLD fMRI activity, and MRS metabolites in 12 SCI patients with neuropathic pain.
VRPG-AKI study
VRPG-AKI study (NCT07722325), Venous Return Pressure Gradient as a Predictor of Acute Kidney Injury: prospective observational cohort testing Pmsf minus CVP within 48 hours of ICU admission as an AKI predictor in at-risk adults; started July 2026, completion estimated May 2027.
VTS trial
The VTS trial, formally the Vertical Transmission Study and locally known as Mamanengane, was a South African cohort study of breastfeeding and postnatal HIV transmission.
Vulva
The vulva (pudendum) is the external female genitalia: mons pubis, labia, clitoris, vestibule, and glands, serving protection, sexual pleasure, and parturition, distinct from the internal vagina.
Vulval pain
Vulval pain, or vulvodynia (primary vulvar pain syndrome), is vulvar pain lasting at least 3 months without identifiable cause, affecting 8-16% of women; classified by location and provocation, treated with variable evidence.
Vulval pruritus
Vulval pruritus (pruritus vulvae, vulvar itching), ICD-11 GA42.0, is intense itching of the external female genitalia, most often caused by vulvovaginal candidiasis and inflammatory dermatoses such as eczema and lichen sclerosus.
Vulval varices
Vulval varices (vulvar varicosities) are varicose veins on the vulva, mostly during pregnancy from pelvic venous congestion; usually symptom-resolving about six weeks postpartum; ICD-11 BD75.2.
Vulvar cancer
Vulvar cancer, also called cancer of the vulva or vulvar carcinoma, is a malignancy of the external female genitalia, mostly squamous cell carcinoma, about half HPV-related, treated surgically with sentinel node biopsy for early disease.
Vulvar cyst
Vulvar cyst (ICD-11 GA13.3): fluid- or keratin-filled sac on the vulva, most often a Bartholin gland cyst affecting 1-2% of women in their 30s; usually benign, treated by drainage, Word catheter, marsupialization, or excision.
Vulvar haematoma
Vulvar haematoma (vulvar hematoma), a blood collection in the vulva, usually after childbirth trauma or perineal injury; managed conservatively when small, surgically when large or expanding.
Vulvar intraepithelial neoplasia
Carcinoma in situ of vulva, also called vulvar intraepithelial neoplasia (VIN), is a noninvasive vulvar precancer; now classified as HPV-related vulvar HSIL and HPV-independent differentiated VIN (dVIN), with dVIN carrying roughly 50% malignant transformation risk.
Vulvar laceration
Vulvar laceration (ICD-11 GA13.6) is a tear of the external female genitalia from childbirth, sexual violence, or accidental trauma; classified by the Sultan degrees, assessed with rectal examination, and often managed without suturing.
Vulvar Paget disease
Vulvar Paget disease, a form of extramammary Paget disease, is a rare in-situ adenocarcinoma of vulvar skin in postmenopausal women, treated mainly by wide excision, with high recurrence and topical imiquimod or radiotherapy as alternatives.
Vulvectomy
Vulvectomy is surgery that removes part or all of the vulva, performed mainly to treat vulvar cancer; it ranges from simple vulvectomy to radical forms with groin node dissection.
Vulvitis
Vulvitis (外陰炎), ICD-11 GA00, is inflammation of the vulva, the external female genitals, from infection, allergy, irritants, injury, or menopause-related atrophy; distinct from vulvovaginitis, which also involves the vagina.
Vulvodynia
Vulvodynia is chronic vulvar pain lasting at least 3 months without an identifiable cause, classified by the 2015 ISSVD/ISSWSH/IPPS consensus. Lifetime prevalence 8–28%; tissue-based therapies show the best treatment evidence.
Vulvovaginal gingival syndrome
Vulvovaginal gingival syndrome, also called vulvovaginal-gingival lichen planus, is a rare erosive lichen planus variant affecting vulval, vaginal, and gingival mucosae, marked by scarring, vaginal stricture, dyspareunia, and adult onset.
Vulvovaginal inflammation
Vulvovaginal inflammation (vulvovaginitis, vaginitis): inflammation of the vulva and vagina causing itching, discharge, odor. Main causes are bacterial vaginosis, candidiasis, trichomoniasis, and noninfectious irritants; diagnosis needs pH, KOH, microscopy, and NAAT.
Vulvovaginal ulceration
Vulvovaginal ulceration (ICD-11 GA00.4): ulcers of the vulva or vagina from STIs such as herpes and syphilis, aphthous or Lipschütz ulcers, dermatoses, trauma, or neoplasms; diagnosis requires laboratory testing.
Vunakizumab
Vunakizumab (SHR-1314, 安达静) is a humanized IgG1 anti-IL-17A monoclonal antibody by Hengrui's Suzhou Suncadia, approved in China (2024) for plaque psoriasis and (2025) for ankylosing spondylitis.